GlobalData: Mutation-prone RSV could hinder vaccine development
The analysis company calls for ”constant surveillance for new mutations” as vaccines begin to enter the market, and warns of the risk of ”viral escape” from an AstraZeneca/Sanofi RSV antibody.
by christian bundgaard, translated by daniel pedersen
Many years of pharmaceutical companies’ work and multimillion-dollar investments into respiratory syncytial virus (RSV) vaccines could be vulnerable to disease mutations, writes analysis company GlobalData in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer and GSK posed for RSV vaccine launches this year
For subscribers
.jpg)
.jpg&w=384&q=75)
